OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Current assets | ||||||||||
Money funds | -11.80%41.56M | -45.99%25.01M | -72.02%22.39M | 329.75%69.24M | 749.73%47.12M | 209.57%46.31M | 52.58%80.01M | -75.69%16.11M | -92.62%5.55M | -75.51%14.96M |
Transactional financial assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --2.51K | --2.57K |
Notes receivable and accounts receivable | -18.34%16.65M | -17.65%28.98M | 85.13%32.8M | -5.04%46.32M | -73.91%20.4M | -28.83%35.19M | 842.53%17.72M | 2,344.89%48.78M | 4,305.09%78.19M | 2,240.65%49.45M |
-Notes receivable | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --3.4M | ---- | ---- |
-Accounts receivable | -18.34%16.65M | -17.65%28.98M | 85.13%32.8M | 2.08%46.32M | -73.91%20.4M | -28.83%35.19M | 842.53%17.72M | 2,174.47%45.38M | 4,305.09%78.19M | 2,240.65%49.45M |
Other receivables (including interest and dividends) | -98.16%601.43K | -24.87%23.35M | 56.72%41.41M | -6.55%34.37M | 12.34%32.69M | -23.83%31.08M | -34.44%26.42M | -8.35%36.77M | -27.79%29.1M | 0.36%40.8M |
-Other receivable | -98.16%601.43K | ---- | 56.72%41.41M | ---- | 12.34%32.69M | ---- | -34.44%26.42M | ---- | -27.79%29.1M | ---- |
Advance payment | -85.39%976.31K | -67.52%13.17M | -7.82%9.31M | -7.84%29.68M | -66.05%6.68M | 1,175.93%40.54M | -88.40%10.1M | 23,463.30%32.2M | 7,491.13%19.69M | 4,428.88%3.18M |
Inventories | -73.43%34.68M | -84.60%29.02M | -85.30%27.97M | -35.53%123.7M | -26.99%130.52M | -2.61%188.44M | 61.62%190.23M | 17,761.46%191.86M | 16,628.36%178.76M | 15,804.44%193.49M |
Receivable financing | 159.13%53.16M | 19,209.22%19.31M | 359.24%27.42M | --29.93M | --20.52M | --100K | --5.97M | ---- | ---- | ---- |
Other current assets | 71.69%21.68M | 7.35%16.62M | -52.09%8.02M | 37.84%7.57M | 130.01%12.63M | 15.18%15.48M | 40.06%16.74M | 282.14%5.49M | 348.06%5.49M | 3,794.99%13.44M |
Adjustment items of current assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---0.01 | ---- | ---- |
Total current assets | -37.42%169.32M | -56.47%155.46M | -51.23%169.31M | 2.89%340.8M | -14.59%270.55M | 13.26%357.14M | 11.49%347.19M | 198.28%331.22M | 164.43%316.77M | 198.94%315.32M |
Non Current assets | ||||||||||
Other equity investment | ---- | ---- | -99.47%1.77M | -67.28%108.28M | -26.94%233.2M | 5.19%325.42M | 3.84%332.74M | -3.24%330.89M | -7.32%319.21M | -14.14%309.37M |
Investment real estate | -8.08%30.2M | -9.45%31.15M | -9.09%32M | -10.84%32.1M | -10.85%32.85M | 1.43%34.4M | 1.45%35.2M | 1.55%36.01M | 1.66%36.85M | -10.51%33.92M |
Long-term equity investment | 3.00%982.14M | 0.65%965.67M | -1.15%960.88M | -2.53%959.09M | 0.70%953.51M | -8.23%959.47M | -8.15%972.02M | -8.65%984.01M | -14.17%946.86M | -4.36%1.05B |
Long term receivable account | --4.86M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Fixed assets | -3.43%93.47M | ---- | -1.66%94.59M | ---- | 19.99%96.79M | ---- | 10.14%96.18M | ---- | -10.44%80.66M | ---- |
Constru in process | 1,254.93%726.46M | ---- | 1,602.24%209.13M | ---- | 647.80%53.62M | ---- | --12.29M | ---- | --7.17M | ---- |
Construction materials | --320.66K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Intangible assets | -4.28%32.22M | -4.27%32.58M | -4.17%32.94M | -4.12%33.3M | -4.08%33.66M | -3.95%34.03M | -2.38%34.37M | -2.32%34.73M | -2.26%35.09M | -2.24%35.43M |
Long deferred expense | 75.54%6.6M | 50.25%5.32M | --4.4M | --4.67M | --3.76M | --3.54M | ---- | ---- | ---- | ---- |
Deferred tax assets | -12.64%49.6M | -4.68%54.49M | -4.63%55.16M | -6.72%55.51M | -5.07%56.77M | 116.26%57.17M | 118.80%57.84M | 125.05%59.51M | 126.15%59.8M | -0.39%26.44M |
Usufruct assets | -11.92%100.71M | -11.57%104.12M | -11.21%107.57M | -10.33%110.99M | -10.06%114.34M | -6.72%117.74M | --121.15M | --123.77M | --127.12M | --126.22M |
Other non current assets | -95.71%3.8M | --32.9M | --156.77M | --191.72M | --88.68M | ---- | ---- | ---- | ---- | ---- |
Total non current assets | 21.79%2.03B | 5.10%1.74B | -0.40%1.66B | 0.05%1.66B | 3.37%1.67B | -0.27%1.66B | 6.37%1.66B | 3.50%1.66B | -1.44%1.61B | 1.20%1.66B |
Adjustment items of total assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0.01 | ---- | ---- |
Total assets | 13.52%2.2B | -5.80%1.9B | -9.18%1.82B | 0.52%2B | 0.43%1.94B | 1.88%2.02B | 7.22%2.01B | 16.10%1.99B | 9.88%1.93B | 13.12%1.98B |
Liabilities | ||||||||||
Current liabilities | ||||||||||
Short term loan | -74.25%41.32M | -84.25%30M | -86.30%30M | -54.82%76.44M | -5.18%160.44M | 12.55%190.44M | 29.42%219M | --169.21M | --169.21M | --169.21M |
Notes payable and accounts payable | 1,257.36%250.09M | -38.22%27.92M | 5.27%21.19M | 17.68%36.81M | -18.73%18.42M | 73.89%45.19M | 1,893.11%20.13M | 2,779.08%31.28M | 856.67%22.67M | 1,179.77%25.99M |
-Accounts payable | 1,257.36%250.09M | -38.22%27.92M | 5.27%21.19M | 17.68%36.81M | -18.73%18.42M | 73.89%45.19M | 1,893.11%20.13M | 2,779.08%31.28M | 856.67%22.67M | 1,179.77%25.99M |
Contract liabilities | 21.64%2.27M | -78.32%1.31M | -46.73%1.9M | -93.08%1.57M | -71.14%1.86M | 207.81%6.03M | -72.76%3.57M | --22.7M | --6.46M | --1.96M |
Advance receipts | -6.71%1.12M | -90.44%618.91K | -10.09%666.22K | 7,245.60%103.99M | 70.14%1.2M | 570.53%6.48M | -49.23%741.02K | 18.37%1.42M | -16.35%702.64K | 15.90%965.99K |
Salaries payable | 31.14%7.24M | 14.49%6.42M | 10.84%6.08M | 6.19%5.38M | 0.18%5.52M | 32.30%5.6M | 46.62%5.48M | 41.97%5.07M | 53.81%5.51M | 21.44%4.24M |
Taxs payable | -61.28%1.45M | 26.21%2.67M | -27.58%4.26M | -38.38%3.74M | -79.58%3.75M | -68.58%2.12M | 126.59%5.88M | 207.37%6.08M | 427.71%18.36M | 284.55%6.74M |
Other payable (including interest and dividends) | -82.62%2.68M | -46.30%5.64M | -8.66%907.46K | 145.04%22.04M | 64.49%15.44M | 1,756.83%10.5M | -8.42%993.48K | 1,904.75%8.99M | 868.37%9.39M | -15.95%565.32K |
-Other payable | -82.62%2.68M | ---- | -8.66%907.46K | ---- | 64.49%15.44M | ---- | -8.42%993.48K | ---- | 868.37%9.39M | ---- |
Non current liabilities due within one year | 253.93%41.27M | -2.55%11.13M | -2.05%11.15M | 7.19%11.66M | 7.19%11.66M | --11.42M | --11.38M | --10.88M | --10.88M | ---- |
Other current liabilities | 506.89%40.17M | 1,827.12%17.58M | 3,335.78%13.4M | 602.59%14.36M | 2,825.60%6.62M | 417.02%912.11K | -66.98%389.89K | --2.04M | --226.27K | --176.42K |
Total current liabilities | 72.33%387.61M | -62.94%103.28M | -66.53%89.55M | 7.11%276M | -7.59%224.92M | 32.81%278.7M | 38.35%267.58M | 3,012.16%257.67M | 2,065.09%243.41M | 2,290.69%209.84M |
Current liabilities | ||||||||||
Long term account payable | --59.13M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Estimate liabilities | --44.26K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Deferred tax liabilities | -67.03%25.19M | -72.97%26.05M | -72.16%27.26M | -48.86%50.6M | -20.44%76.39M | 56.03%96.4M | 51.68%97.91M | 41.49%98.94M | 36.11%96.02M | -16.19%61.78M |
Long term deferred income | --3.86M | --5.06M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Lease liabilities | -12.52%85.54M | -10.75%93.76M | -10.71%92.58M | -11.10%90.85M | -10.19%97.78M | -13.33%105.05M | --103.68M | --102.2M | --108.88M | --121.2M |
Total non current liabilities | -0.24%173.76M | -23.62%153.87M | -40.55%119.84M | -29.68%141.45M | -15.00%174.17M | 10.09%201.45M | 212.30%201.59M | 187.62%201.14M | 190.44%204.9M | 148.23%182.99M |
Total liabilities | 40.66%561.37M | -46.44%257.15M | -55.37%209.39M | -9.01%417.45M | -10.98%399.1M | 22.23%480.15M | 81.88%469.17M | 486.62%458.81M | 448.12%448.31M | 376.19%392.83M |
Shareholders equity | ||||||||||
Paid-in capital | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M | 0.00%484.93M |
Other equity instruments | ---- | ---- | ---- | --578.47M | ---- | ---- | ---- | ---- | ---- | ---- |
Capital reserve funds | 0.45%581.06M | 0.00%578.47M | 0.00%578.47M | ---- | 0.00%578.47M | 0.00%578.47M | 0.00%578.47M | 0.00%578.47M | 0.00%578.47M | 0.00%578.47M |
Surplus reserve funds | 13.11%140.22M | 0.00%123.97M | 0.00%123.97M | 0.00%123.97M | 0.00%123.97M | 0.00%123.97M | 0.00%123.97M | 0.00%123.97M | 0.00%123.97M | 4.99%123.97M |
Retained profit | 102.45%432.9M | 203.42%469.19M | 184.68%431.28M | 122.30%334.72M | 101.41%213.83M | -28.15%154.63M | -36.48%151.5M | -37.73%150.57M | -61.55%106.17M | -19.38%215.2M |
Other composite income | -100.58%-791.45K | -106.93%-13.51M | -101.76%-3.53M | -67.56%63.54M | -26.77%137.42M | 5.71%195.01M | 5.81%200.92M | -6.25%195.88M | -10.96%187.67M | -15.92%184.48M |
Shareholders equity without minority interests | 6.48%1.64B | 6.90%1.64B | 4.89%1.62B | 3.38%1.59B | 3.88%1.54B | -3.15%1.54B | -4.70%1.54B | -6.37%1.53B | -11.53%1.48B | -4.84%1.59B |
Total shareholder equity | 6.48%1.64B | 6.90%1.64B | 4.89%1.62B | 3.38%1.59B | 3.88%1.54B | -3.15%1.54B | -4.70%1.54B | -6.37%1.53B | -11.53%1.48B | -4.84%1.59B |
Total liabilityies and equity | 13.52%2.2B | -5.80%1.9B | -9.18%1.82B | 0.52%2B | 0.43%1.94B | 1.88%2.02B | 7.22%2.01B | 16.10%1.99B | 9.88%1.93B | 13.12%1.98B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | ZTE Accounting firm (Special General Partnership) | -- | -- | -- | ZTE Accounting firm (Special General Partnership) | -- | -- | -- | ZTE Accounting firm (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.